Qiagen to Acquire Stake in Alacris
Qiagen to acquire stake in Alacris, gaining access to biomarker pipeline for use in personalized healthcare assays. Alacris Theranostics is a German start-up company using novel technologies to develop individualized cancer treatment strategies based upon a patient's genomic profile. Qiagen will have an exclusive option to access all biomarkers emerging from this discovery program.
Alacris, founded by researchers at the Max Planck Institute for Molecular Genetics (MPI-MG) in Berlin and Harvard Medical School in Cambridge, USA, uses a proprietary modeling system developed at MPI-MG and exclusively licensed to Alacris Theranostics, to analyze clinical sample data based on next-generation and other whole genome sequencing technologies. This system, called ModCell, addresses a critical bottleneck in the development of personalized healthcare solutions. It allows users to identify and select from vast amounts of genetic data such markers that can prove useful to guide treatment decisions for patients. The technology can also be used to create marker subsets to stratify potential patient populations for R&D trials involving medicines in clinical development. These marker selections can be formatted into real-time PCR-based assays that Qiagen can commercialize within its pharmaceutical development assay portfolio or its therascreen molecular diagnostics portfolio for use on its new QIAsymphony RGQ platform.